首页> 中文期刊> 《中国畜牧兽医》 >复方诃子口服液抗犊牛大肠杆菌性腹泻的药理作用研究

复方诃子口服液抗犊牛大肠杆菌性腹泻的药理作用研究

         

摘要

The aim of the experiment was to study the pharmacological effects of compound Myrobalanoral liquid against Escherichia coli (E.coli) diarrhea in calves.We used neutralize enterotoxin test, anti-exudation test, antipyretic test, analgesic test, intestinal peristalsis test and immunomodulation test to verify the pharmacological effects of compound Myrobalan oral liquid.Theresults showed that in the neutralize enterotoxin test, there was extremely significant difference between compound Myrobalanoral liquid and negative control groups (P0.05) .In the antipyretic test, the high-dose group of compound Myrobalan oral liquid quickly inhibited the increase of body temperature 1hafter administration, and the increase of body temperature was inhibited 2hafter the administration in medium dose group;3h after the administration, the body temperature was significantly reduced in high and medium dose groups compared with model group;The difference between low dose and model groups was not significant.In the anti-analgesic test, there were extremely significant differences in aspirin group, compound Myrobalanoral liquid high and medium dose groups compared with blank group (P0.05) .In the intestinal peristalsis test, compared with blank group, compound Myrobalan oral liquid high dose and atropine sulphate groups had obviously inhibitory effect on intestinal peristalsis (P0.05) .In the immunomodulation test, the white blood cell (WBC) count, spleen and thymus organ indexes in model group were significantly lower than those in blank group (P<0.05) , and the WBC count, spleen and thymus organ indexes in compound Myrobalan oral liquid group were significantly higher than those in model group on the 14 th day (P<0.05) .In conclusion, compound Myrobalan oral liquid had neutralize enterotoxin, anti-exudation of tissue fluid, antipyretic, analgesia and inhibitory effect on intestinal peristalsis of E.coli diarrhea, and could enhance the immune function and other pharmacological effects.%试验旨在研究抗犊牛大肠杆菌性腹泻的复方诃子口服液的药理作用, 采用中和毒素试验、抗渗出试验、解热试验、镇痛试验、肠蠕动试验及免疫调节试验的方法, 验证复方诃子口服液的药理作用.结果显示, 抗毒素中和试验中, 复方诃子口服液组与阴性对照组差异极显著 (P<0.01) .抗渗出试验中, 各药物组均能不同程度地减少伊文思蓝的渗出, 阿司匹林组及复方诃子口服液高、中、低剂量组的抑制率分别为58.1%、42.8%、31.6%和14.9%, 其中复方诃子口服液低剂量组与空白组相比差异显著 (P<0.05), 其余各组与空白组相比均差异极显著 (P<0.01);复方诃子口服液各剂量组与阿司匹林组相比, 高剂量组差异不显著 (P>0.05), 中、低剂量组差异极显著 (P<0.01) .解热试验中, 复方诃子口服液高剂量组给药后1h快速抑制体温升高, 中剂量组给药后2h抑制体温升高;给药后3h, 与模型组相比, 复方诃子口服液高、中剂量组体温均明显降低, 低剂量组与模型组差异不明显.镇痛试验中, 与空白组相比, 阿司匹林组、复方诃子口服液高、中剂量组镇痛效果差异极显著 (P<0.01), 扭体抑制率分别为64.55%、52.73%和32.73%, 疼痛潜伏期分别为9.59、6.33和5.74min;而复方诃子口服液低剂量组差异不显著 (P>0.05) .肠蠕动试验中, 与空白组相比, 硫酸阿托品组及复方诃子口服液高剂量组对肠蠕动抑制作用差异极显著 (P<0.01), 推进率分别为44.18%和52.55%, 复方诃子口服液中剂量组差异显著 (P<0.05), 低剂量组差异不显著 (P>0.05) .免疫调节试验中, 与空白组相比, 模型组白细胞数、脾脏指数及胸腺指数均显著降低 (P<0.05);而与模型组相比, 第14天复方诃子口服液组白细胞数、脾脏指数及胸腺指数均显著提高 (P<0.05) .综上所述, 复方诃子口服液对犊牛大肠杆菌性腹泻具有抑制肠蠕动、解热、抗疼痛和组织液渗出、中和肠毒素及增强免疫功能等药理作用.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号